Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Accelerated rTMS for Apathy in Parkinson's Disease

NCT: NCT07399496 · RECRUITING

NCT IDNCT07399496
StatusRECRUITING
Start Date2026-09-15
Completion2027-08-15
SponsorMedical University of South Carolina (OTHER)
First posted
Last updated

Brief Summary

This single-site, open-label pilot study will evaluate the feasibility, tolerability, and preliminary efficacy of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo six treatment visits over two weeks, receiving eight iTBS sessions per day. Outcomes include adherence, tolerability, changes in apathy (Lille Apathy Rating Scale), functional engagement, and neural target engagement assessed via resting-state fMRI and EEG. Follow-up assessments will occur at two and four weeks post-treatment.

Frequently Asked Questions

What is Accelerated rTMS for Apathy in Parkinson's Disease?

Accelerated rTMS for Apathy in Parkinson's Disease is a clinical trial registered under NCT07399496. Current status: RECRUITING.

What is the status of NCT07399496?

The current status of NCT07399496 (Accelerated rTMS for Apathy in Parkinson's Disease) is: RECRUITING.

When did Accelerated rTMS for Apathy in Parkinson's Disease start?

Accelerated rTMS for Apathy in Parkinson's Disease started on 2026-09-15.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.